Eugene D. Kwon

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

N. Agarwal, C. Drake, H. Scher, 2014, The Lancet. Oncology.